Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
13.06
-0.59 (-4.32%)
Jul 6, 2026, 2:37 PM EDT - Market open
Atrium Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Atrium Therapeutics stock have an average target of $25, which predicts a 91.42% increase from the current stock price of 13.06.
Price Target: $25 (+91.42%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Atrium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 3 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $25 | Buy | Initiates | $25 | +91.42% | Jun 18, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +91.42% | May 15, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $25 | Buy | Initiates | $25 | +91.42% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
21.60M
from 18.62M
Increased by 16.02%
Revenue Next Year
2.67M
from 21.60M
Decreased by -87.65%
EPS This Year
-3.59
EPS Next Year
-5.85
from -3.59
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.6M | ||
| Avg | 21.6M | ||
| Low | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.5% | ||
| Avg | 16.0% | ||
| Low | 5.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.59 | ||
| Avg | -3.59 | ||
| Low | -3.59 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |